Tag - Corbus Pharmaceuticals

Corbus Pharma (CRBP) Announces Proposed Public Common Offering

Ziad2022-11-25T14:05:29-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) today announced that it plans to offer shares of its common stock in an underwritten public offering. Read more >>

Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

Ziad2022-11-25T14:05:30-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology ("ACR") 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California. Read more >>

Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Ziad2022-11-25T14:05:30-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 8:35 a.m. EDT in New York, NY. Read more >>

Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD

Ziad2022-11-25T14:05:30-05:00Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will host a live video webcast (details below) on Tuesday, September 5, 2017 at 12:00 PM ET to discuss dermatomyositis: the disease, its treatment, and its impact on patients' lives. Read more >>

Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End

Ziad2022-11-25T14:05:30-05:00Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth quarter of 2017, putting the treatment a step closer toward regulatory approval after a Phase 2 trial that improved patients’ disease. Read more >>

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

Ziad2022-11-25T14:05:31-05:00Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. Read more >>

Corbus Pharmaceuticals: Best Places to Work 2017 rankings

Ziad2022-11-25T14:05:41-05:00Corbus Pharmaceuticals has been named one of the Best Places to Work in 2017. Read more >>

Corbus Pharmaceuticals Gets a Buy Rating from Noble Financial

Ziad2022-11-25T14:05:42-05:00Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Read more >>

Anabasum: A Potential Treatment for Systemic Sclerosis

Ziad2022-11-25T14:05:53-05:00Corbus CMO Dr. Barbara White, CEO Dr. Yuval Cohen and Dr. Michael Whitfield of Dartmouth University discuss the Phase 2 results of anabasum in systemic sclerosis and its potential to improve the quality of life for patients. Watch now >>

Corbus Pharma outlines U.S. approval path for lead drug

Ziad2022-11-25T14:05:53-05:00The U.S. Food and Drug Administration needs Corbus Pharmaceuticals to show positive data from only one late-stage study on its experimental treatment for scleroderma to support a marketing application, the company said. Read more >>